Sandra Codony,Carla Calvó-Tusell,Elena Valverde,Sílvia Osuna,Christophe Morisseau,M. Isabel Loza,José Brea,Concepción Pérez,María Isabel Rodríguez-Franco,Javier Pizarro-Delgado,Rubén Corpas,Christian Griñán-Ferré,Mercè Pallàs,Coral Sanfeliu,Manuel Vázquez-Carrera,Bruce D. Hammock,Ferran Feixas,Santiago Vázquez,Carla Calvó-Tusell,Sílvia Osuna,José Brea,Concepción Pérez,María Isabel Rodríguez-Franco,Rubén Corpas,Christian Griñán-Ferré,Mercè Pallàs,Manuel Vázquez-Carrera,Santiago Vázquez

Abstract:The pharmacological inhibition of soluble epoxide hydrolase (sEH) is efficient for the treatment of inflammatory and pain-related diseases. Numerous potent sEH inhibitors (sEHIs) present adamantyl or phenyl moieties, such as the clinical candidates AR9281 or EC5026. Herein, in a new series of sEHIs, these hydrophobic moieties have been merged in a benzohomoadamantane scaffold. Most of the new sEHIs have excellent inhibitory activities against sEH. Molecular dynamics simulations suggested that the addition of an aromatic ring into the adamantane scaffold produced conformational rearrangements in the enzyme to stabilize the aromatic ring of the benzohomoadamantane core. A screening cascade permitted us to select a candidate for an in vivo efficacy study in a murine model of cerulein-induced acute pancreatitis. The administration of 22 improved the health status of the animals and reduced pancreatic damage, demonstrating that the benzohomoadamantane unit is a promising scaffold for the design of novel sEHIs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01601?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01601</a>.1H and 13C NMR spectra and elemental analysis data of the new compounds, HPLC trace for compound 22, representation of the active site volume fluctuations, non-covalent interactions between the inhibitors and the active site residues of sEH, analysis of active site water molecules in MD simulations, plots of the dihedral angle that describes the rotation of the benzohomoadamantane and adamantane moieties in the left-hand-side pocket of the sEH active site along the MD simulations, overlay of the X-ray and representative snapshot from the apo state and inhibitor-bound aMD simulations, pharmacokinetic data of compounds 20 and 22, and histologic scoring of pancreatic tissues of mice treated with 22 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01601/suppl_file/jm0c01601_si_001.pdf">PDF</a>).Molecular formula strings and data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01601/suppl_file/jm0c01601_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

The 5-Substituted Piperazine As a Novel Secondary Pharmacophore Greatly Improving the Physical Properties of Urea-Based Inhibitors of Soluble Epoxide Hydrolase.

Structure-Based Optimization of the Piperazino-Containing 1,3-Disubstituted Ureas Affording Sub-Nanomolar Inhibitors of Soluble Epoxide Hydrolase

Discovery and optimization of piperazine urea derivatives as soluble epoxide hydrolase (sEH) inhibitors

Insight into the binding modes and inhibition mechanisms of adamantyl-based 1,3-disubstituted urea inhibitors in the active site of the human soluble epoxide hydrolase.

Progress on the Treatment for Hypertension of Epoxide Hydrolase and Its Mechanisms

Design, Synthesis, and In‐Vitro Evaluation of Novel Butanoic Acid Derivatives as Potential Soluble Epoxide Hydrolase Inhibitors

Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain

Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors

Discovery of glycosidated glycyrrhetinic acid derivatives: Natural product-based soluble epoxide hydrolase inhibitors

Discovery of memantyl urea derivatives as potent soluble epoxide hydrolase inhibitors against lipopolysaccharide-induced sepsis

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Synthesis, In Vitro Enzymatic Inhibition, and Molecular Modeling of Novel Piperazine‐Based Bis‐Schiff Base Derivatives as Promising Anti‐urease Agents

Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy

Development of Potent Inhibitors of the Human Microsomal Epoxide Hydrolase

From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis

Synthesis and biological evaluation of pyridylpiperazine hybrid derivatives as urease inhibitors

Benzoxazolone-5-Urea Derivatives as Human Soluble Epoxide Hydrolase (sEH) Inhibitors

Synthesis, In Vivo, ADME Determination, and Molecular Docking Studies of 1,3,4‐Oxadiazoles Containing Pyridine and Piperazine Moieties as New Diuretic Agents

Synthesis, Evaluation and Mechanism Exploration of 2-(N-(3-nitrophenyl)-n-phenylsulfonyl)aminoacetohydroxamic Acids As Novel Urease Inhibitors.

Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products